Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines.
Recombinant human interferon beta (rIFN-beta) inhibited in a time- and dose-dependent manner the proliferation of 18/18 human colon carcinoma cell lines in monolayer culture and 8/9 lines in a soft agar assay but had no effect on 4 human fibroblast cell lines. Maximal inhibition of cell proliferation by rIFN-beta required repetitive treatment (every 2 days) with lymphokine (50 units/ml). Furthermore, the inhibitory activity of rIFN-beta was neutralized by polyclonal antibodies against natural IFN-beta. In contrast to rIFN-beta, rIFN-alpha was inactive against all colon cell lines tested, and rIFN-gamma, with the exception of HT-29 cells, was similarly ineffective. These data demonstrate that rIFN-beta is a potent growth inhibitor of colon carcinoma cells in vitro, and suggest that studies on its mechanism of action may lead to a better understanding of the regulation of colon tumor cell proliferation.
Wong
V L
VL
Department of Cell Biology, Smith Kline and French Laboratories, King of Prussia, PA 19406.
Rieman
D J
DJ
Aronson
L
L
Dalton
B J
BJ
Greig
R
R
Anzano
M A
MA
D000230:Adenocarcinoma / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology; D011994:Recombinant Proteins; D013997:Time Factors; D014407:Tumor Cells, Cultured
D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma